Electroceuticals

1. Global Electroceuticals Market Global Electroceuticals Market Insights The Global Electroceuticals Market was valued at USD 16.80 Billion in 2021, and it is expected to reach a value of USD 23.64 Billion by 2028, at a CAGR of 5.0% over the forecast period (2022 - 2028). Electroceuticals are medical devices that are used to help patients regain their health by either holding the device against their skin or implanting it into their nerves. It's also known as bioelectric medicine, and it's an alternative to a drug- based treatment option. Most of the time, electroceuticals are not the first line of treatment, rather these devices are only utilized when drugs are unable to restore the patient's health. The majority of electroceuticals do not cure the disease, rather they do relieve the discomfort or bypass the problematic area of the body. Neurostimulation, or the control of the neurological system by electrical impulses, is the basis for electroceuticals. Electroceutical devices have been used to treat a variety of illnesses and problems related to cardiology and neurology.

2. Electroceuticals are also proven in treating these conditions in both invasive as well as non-invasive methods. Know more about : https://skyquestt.com/report/electroceuticals-market Global Electroceuticals Market Segmental Analysis The Global Electroceuticals Market is segmented based on Product, End-User, and, Region. Based on the product, the Global Electroceuticals Market is segmented into Defibrillators and Pacemaker, Deep Brain Stimulators, Spinal Cord Stimulators, Vagus Nerve Stimulators, Hearing Aids and Cochlear Implants, and Others. Based on the end-user, the Global Electroceuticals Market is segmented into Hospitals & Clinics and Homecare & Others. Based on the region, the Global Electroceuticals Market is segmented into North America, Europe, Asia-Pacific, South America, and MEA. Top Players' Company Profiles •Medtronic plc (Ireland) •Boston Scientific Corporation (US) •Abbott Laboratories, Inc. (US) •LivaNova PLC (UK) •Cochlear Ltd. (Australia) •MicroPort Scientific Corporation (China) •Sonova Group (Switzerland) •Nevro Corp. (US) •NeuroPace, Inc. (US) •BIOTRONIK (Germany) •Medico S.p.A. (Italy) •Nurotron Biotechnology Co. Ltd. (US) •MED-EL (Austria) •Aleva Neurotherapeutics SA (Switzerland) •NeuroSigma, Inc. (US) •Bioinduction Ltd. (UK) Get free sample pdf report copy at https://skyquestt.com/sample- request/electroceuticals-market

3. Recent Developments •In March 2022, the UK-based company Rapid Response Revival launched CellAED, which is created to increase access to defibrillators and overcome barriers to their use. It is a personal, portable defibrillator that uses game-changing technology, designed to improve the chances of surviving a sudden cardiac arrest. The company claims the newly designed CellAED to be quick and easy to use. CellAED is up to one-tenth of the price, size, and weight of current technology. •In February 2022, Abbott announced the launch of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i pivotal clinical study. •In January 2022, Cochlear Limited, a key player in implantable hearing solutions, received US Food and Drug Administration (FDA) approval for its Cochlear Nucleus Implants which are used for the treatment of unilateral hearing loss (UHL)/single-sided deafness (SSD).